Inhibition of proliferation and induction of G1-phase cell-cycle arrest by dFMGEN, a novel genistein derivative, in lung carcinoma A549 cells

Drug and Chemical Toxicology

Volumn 36, Issue 2, 2013, Pages 196-204

  Peng, Bo ^a,b,c   Cao, Jianguo ^d   Yi, Sisi ^a   Wang, Chengkun ^a   Zheng, Guopei ^a   He, Zhimin ^a,b  

^a Central South University   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF SOUTH CHINA   (China)

^d HUNAN NORMAL UNIVERSITY   (China)

Author keywords

7 difluoromethyl 5,4 dimethoxygenistein; Cdk; Cell cycle; Chemotherapeutical; Cyclin; Genistein

Indexed keywords

7 DIFLUOROMETHYL 5,4 'DIMETHOXYGENISTEIN; ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; GENISTEIN; PROTEIN P15; PROTEIN P21; PROTEIN P27; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL LEVEL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CARCINOMA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; DOSE-RESPONSE RELATIONSHIP, DRUG; G1 PHASE CELL CYCLE CHECKPOINTS; GENISTEIN; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 84871198345     PISSN: 01480545     EISSN: 15256014     Source Type: Journal    
DOI: 10.3109/01480545.2012.710620     Document Type: Article

References (30)

1. Aminimoghadamfarouj, N., Nematollahi, A., Wiart, C. (2011). Annonaceae: Bio-resource for tomorrow's drug discovery. J Asian Nat Prod Res 13:465-476.
2. Bible, K. C., Kaufmann, S. H. (1996). Flavopiridol: A cytotoxic flavones that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56:4856-4861.
3. Chang, G. C., Hsu, S. L., Tsai, J. R., Liang, F. P., Lin, S. Y., Sheu, G. T., et al. (2004). Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem Pharmacol 68:1453-1464.
4. Chen, J., Lin, H., Hu, M. (2005). Absorption and metabolism of genistein and its five isoflavone analogs in the human intestinal Caco-2 model. Cancer Chemother Pharmacol 55:159-169.
5. Ferreira, S. B., Costa, M. S., Boechat, N., Bezerra, R. J., Genestra, M. S., Canto-Cavalheiro, M. M., et al. (2007). Synthesis and evaluation of new difluoromethyl azoles as antileishmanial agents. Eur J Med Chem 42:1388-1395.
6. Fu, X. H., Wang, L., Zhao, H., Xiang, H. L., Cao, J. G. (2008). Synthesis of genistein derivatives and determination of their protective effects against vascular endothelial cell damages caused by hydrogen peroxide. Bioorg Med Chem Lett 18:513-517.
7. Guo, R., Cao, Y. Y., Dai, Z. Z., Zhuang, J. Y. (1981). [Characteristics of a human diploid cell line, KMB-17]. [Article in Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 3:226-230.
8. Haddadin, S., Perry, M. C. (2011). History of small-cell lung cancer. Clin Lung Cancer 12:87-93.
9. Johnson, N., Shapiro, G. I. (2010). Cyclin-dependent kinases (cdks) and the DNA damage response: Rationale for cdk inhibitorchemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets 14:1199-1212.
10. Kastan, M. B., Bartek, J. (2004). Cell-cycle checkpoints and cancer. Nature 432:316-323.
11. Kataoka, K., Suzuki, R., Taniguchi, H., Noda, Y., Shindoh, J., Matsumoto, S., et al. (2006). Phase I/II trial of docetaxel and carboplatin as a first-line therapy in patients with stage IV non-small-cell lung cancer. Lung 184:133-139.
12. Krystof, V., Uldrijan, S. (2010). Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets 11:291-302.
13. Kwon, S. H., Kim, S. Y., Ha, K. W., Kang, M. J., Huh, J. S., Im, T. J., et al. (2007). Pharmaceutical evaluation of genistein-loaded pluronic micelles for oral delivery. Arch Pharm Res 30:1138-1143.
14. Li, M., Zhang, Z., Hill, D. L., Chen, X., Wang, H., Zhang, R. (2005). Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res 65:8200-8208.
15. Lu, X., Jung, J., Cho, H. J., Lim, D. Y., Lee, H. S., Chun, H. S., et al. (2005). Fisetin inhibits the activities of cyclin-dependent kinases leading to cell cycle arrest in HT-29 human colon cancer cells. J Nutr 135:2884-2890.
16. Paulo, A., Mota-Filipe, H. (2006). Effects of some natural 5-hydroxyisoflavones on cultured human endothelial cells in presence and absence of hydrogen peroxide. J Pharm Pharmacol 58:101-105.
17. Proskuryakov, S. Y., Konoplyannikov, A. G., Gabai, V. L. (2003). Necrosis: A specific form of programmed cell death? Exp Cell Res 283:1-16.
18. Raez, L. E., Lilenbaum, R. (2006). New developments in chemotherapy for advanced non-small cell lung cancer. Curr Opin Oncol 18:156-161.
19. Ravindranath, M. H., Muthugounder, S., Presser, N., Viswanathan, S. (2004). Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol 546:121-165.
20. Rowland, I., Faughnan, M., Hoey, L., Wahala, K., Williamson, G.,Cassidy, A. (2003). Bioavailability of phyto-oestrogens. Br J Nutr 89(SUPPl1):S45-S58.
21. Santell, R. C., Kieu, N., Helferich, W. G. (2000). Genistein inhibits growth of estrogen-independent human breast cancer cells in culture but not in athymic mice. J Nutr 130:1665-1669.
22. Shah, M. A., Schwartz, G. K. (2001). Cell cycle-mediated drug resistance: An emerging concept in cancer therapy. Clin Cancer Res 7:2168-2181.
23. Shanmugam, M. K., Kannaiyan, R., Sethi, G. (2011). Targeting cell signaling and apoptotic pathways by dietary agents: Role in the prevention and treatment of cancer. Nutr Cancer 63:161-173.
24. Shon, Y. H., Park, S. D., Nam, K. S. (2006). Effective chemopreventive activity of genistein against human breast cancer cells. J Biochem Mol Biol 39:448-451.
25. Swanton, C. (2004). Cell-cycle targeted therapies. Lancet Oncol 5:27-36.
26. Wachsberger, P. R., Burd, R., Marero, N., Daskalakis, C., Ryan, A., McCue, P., et al. (2005). Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 11:835-842.
27. Wang, J., Shang, F., Jiang, R., Liu, L., Wang, S., Hou, J., et al. (2007). Nitric oxide-donating genistein prodrug: Design, synthesis, and bioactivity on MC3T3-E1 cells. J Pharmacol Sci 104:82-89.
28. Wang, L., Zheng, X., Xiang, H. L., Fu, X. H., Cao, J. G. (2009). 7-Difluoromethyl-5,4'-dimethoxygenistein inhibits oxidative stress induced adhesion between endothelial cells and monocytes via NF-kappaB. Eur J Pharmacol 605:31-35.
29. Zhang, Y., Li, X. L., Yao, X. S., Wong, M. S. (2008). Osteogenic activities of genistein derivatives were influenced by the presence of prenyl group at ring A. Arch Pharm Res 31:1534-1539.
30. Zhao, H., Li, C., Cao, J. G., Xiang, H. L., Yang, H. Z., You, J. L., et al. (2009). 7-Difluoromethyl-5,4'-dimethoxygenistein, a novel genistein derivative, has therapeutic effects on atherosclerosis in a rabbit model. J Cardiovasc Pharmacol 54:412-420.